Literature DB >> 14563529

DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193.

N Hajji1, N Pastor, S Mateos, I Domínguez, F Cortés.   

Abstract

The bis-dioxopiperazine ICRF-193 has long time been considered as a pure topoisomerase II catalytic inhibitor able to exert its inhibitory effect on the enzyme without stabilization of the so-called cleavable complex formed by DNA covalently bound to topoisomerase II. In recent years, however, this concept has been challenged, as a number of reports have shown that ICRF-193 really "poisons" the enzyme, most likely through a different mechanism from that shown by the classical topoisomerase II poisons used in cancer chemotherapy. In the present investigation, we have carried out a study of the capacity of ICRF-193 to induce DNA strand breaks, as classical poisons do, in cultured V79 and irs-2 Chinese hamster lung fibroblasts using the comet assay and pulsed-field gel electrophoresis (PFGE). Our results clearly show that ICRF-193 readily induces breakage in DNA through a mechanism as yet poorly understood.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563529     DOI: 10.1016/s0027-5107(03)00135-0

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  15 in total

Review 1.  Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.

Authors:  Yousaf Ali; Shafida Abd Hamid
Journal:  Tumour Biol       Date:  2015-10-20

2.  Type II topoisomerase activities in both the G1 and G2/M phases of the dinoflagellate cell cycle.

Authors:  Carmen K M Mak; Victor K L Hung; Joseph T Y Wong
Journal:  Chromosoma       Date:  2005-11-15       Impact factor: 4.316

3.  Rad9A is required for G2 decatenation checkpoint and to prevent endoreduplication in response to topoisomerase II inhibition.

Authors:  Deborah A Greer Card; Megan L Sierant; Scott Davey
Journal:  J Biol Chem       Date:  2010-03-21       Impact factor: 5.157

4.  The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.

Authors:  V Ashutosh Rao; Sarah R Klein; Keli K Agama; Eriko Toyoda; Noritaka Adachi; Yves Pommier; Emily B Shacter
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 5.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

6.  A mitotic topoisomerase II checkpoint in budding yeast is required for genome stability but acts independently of Pds1/securin.

Authors:  Catherine A Andrews; Amit C Vas; Brian Meier; Juan F Giménez-Abián; Laura A Díaz-Martínez; Julie Green; Stacy L Erickson; Kristyn E Vanderwaal; Wei-Shan Hsu; Duncan J Clarke
Journal:  Genes Dev       Date:  2006-05-01       Impact factor: 11.361

7.  Topoisomerase IIalpha controls the decatenation checkpoint.

Authors:  Kuntian Luo; Jian Yuan; Junjie Chen; Zhenkun Lou
Journal:  Nat Cell Biol       Date:  2008-12-21       Impact factor: 28.824

8.  Defective decatenation checkpoint function is a common feature of melanoma.

Authors:  Kelly Brooks; Kee Ming Chia; Loredana Spoerri; Pamela Mukhopadhyay; Matthew Wigan; Mitchell Stark; Sandra Pavey; Brian Gabrielli
Journal:  J Invest Dermatol       Date:  2013-06-13       Impact factor: 8.551

9.  Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue.

Authors:  Patrick Chène; Joëlle Rudloff; Joseph Schoepfer; Pascal Furet; Peter Meier; Zhiyan Qian; Jean-Marc Schlaeppi; Rita Schmitz; Thomas Radimerski
Journal:  BMC Chem Biol       Date:  2009-01-07

10.  Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.

Authors:  Lars H Jensen; Marielle Dejligbjerg; Lasse T Hansen; Morten Grauslund; Peter B Jensen; Maxwell Sehested
Journal:  BMC Pharmacol       Date:  2004-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.